Can antimalarials be safely used in early pregnancy? a massive registry seeks answers

NCT ID NCT04825782

Completed Knowledge-focused Sponsor: Liverpool School of Tropical Medicine Source: ClinicalTrials.gov ↗

First seen Aug 14, 2026 · Last updated Aug 14, 2026

Summary

This large observational study across multiple African sites tracks pregnant women who use antimalarial drugs, especially in the first trimester. The goal is to assess whether these medications are linked to miscarriage, stillbirth, or major birth defects. By following thousands of pregnancies, researchers hope to generate robust evidence on the safety of these common treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Antimalarial medications
What this could lead to: If successful, this registry could provide clearer safety data on antimalarials in early pregnancy, helping guide safer treatment choices for pregnant women.
What could go wrong: As an observational registry, it cannot prove cause and effect, and results may be affected by underlying health conditions or incomplete follow-up.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CONGENITAL ANOMALY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Congenital Abnormalities malaria pregnancy disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CONGENITAL ANOMALY MALARIA IN PREGNANCY PREGNANCY RELATED

Contacts and locations

Locations

Irss/Crun

Nanoro, Burkina Faso
Kenya Medical Research Institute

Kisumu, 40100, Kenya

More trials for these conditions

Other studies related to the condition(s) this trial covers.